Welcome to LookChem.com Sign In|Join Free

CAS

  • or

154709-18-9

Post Buying Request

154709-18-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 5-[4’-Hydroxymethyl-(1,1’-biphenyl)-2-yl]-1-triphenylmethyltetrazole

    Cas No: 154709-18-9

  • No Data

  • No Data

  • No Data

  • BOC Sciences
  • Contact Supplier

154709-18-9 Usage

Chemical Properties

White Solid

Uses

Intermediate in the preparation of Losartan impurity J.

Check Digit Verification of cas no

The CAS Registry Mumber 154709-18-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,4,7,0 and 9 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 154709-18:
(8*1)+(7*5)+(6*4)+(5*7)+(4*0)+(3*9)+(2*1)+(1*8)=139
139 % 10 = 9
So 154709-18-9 is a valid CAS Registry Number.

154709-18-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name [4-[2-(1-trityltetrazol-5-yl)phenyl]phenyl]methanol

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:154709-18-9 SDS

154709-18-9Relevant articles and documents

Method for synthesizing olmesartan medoxomil intermediate impurities

-

Paragraph 0033; 0037; 0038; 0039; 0042; 0046; 0047; 0048, (2017/07/21)

The invention relates to the field of medicines and in particular relates to a method for synthesizing olmesartan medoxomil intermediate impurities. The olmesartan medoxomil intermediate impurities respectively refer to an impurity C, an impurity D and an impurity F. The respective synthetic reaction equations of the impurities are shown in the followings. The method specifically comprises the following steps: (1) taking an intermediate I as a raw material, and performing reactive deprotection with acetic acid so as to obtain the impurity C; (2) hydrolyzing an initial material B {4-[2-(trityl tetrazol-5-yl)phenyl] benzyl bromide} in a reaction system so as to obtain the impurity D; and (3) hydrolyzing an intermediate II into carboxylic acid in the reaction system, thereby obtaining the impurity F. According to the synthetic method for preparing the impurities, disclosed by the invention, a high-purity reference substance is conveniently obtained, and due to the optimized process, production of the impurities is specifically controlled, so that the quality of the raw drugs is improved. The reaction equation of the impurity C is as shown in the specification. The reaction equation of the impurity D is as shown in the specification. The reaction equation of the impurity F is as shown in the specification.

Preparation of 5 - (4 the [...] -bromo methyl-2-biphenyl) - 1-trityl tetrazazole method

-

Paragraph 0040; 0043, (2017/02/24)

The invention discloses a method for preparing 5-(4'-bromomethyl-2-biphenyl)-1-triphenyl methyl tetrazole. According to the method, 2-cyano biphenyl is used for replacing 2-cyano 4'-methyl biphenyl in the conventional process and is used as a starting material, and a target product, the 5-(4'-bromomethyl-2-biphenyl)-1-triphenyl methyl tetrazole, is obtained by means of hydroxymethylation, cyclization, protection, and substitution reaction. The method has the advantages of low cost of the raw materials, convenience for recovery of solvent, less comprehensive pollution and the like and is suitable for industrialized production.

New nonpeptide angiotensin II receptor antagonists. 2. Synthesis, biological properties, and structure-activity relationships of 2-alkyl-4- (biphenylylmethoxy)quinoline derivatives

Bradbury,Allott,Dennis,Fisher,Major,Masek,Oldham,Pearce,Rankine,Revill,Roberts,Russell

, p. 4027 - 4038 (2007/10/02)

A novel series of nonpeptidic angiotensin II (AII) receptor antagonists is reported, derived from linkage of the biphenylcarboxylic acid or biphenylyltetrazole moiety found in previously described antagonists via a methyleneoxy chain to the 4-position of

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 154709-18-9